<p>High-rolling investors have positioned themselves bearish on Insmed (NASDAQ:INSM), and it's important for retail traders to take note.
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in INSM often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Insmed. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 12% bullish and 75% bearish. Among all the options we identified, there was one put, amounting to $27,207, and 7 calls, totaling $347,874.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $32.5 and $200.0 for Insmed, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Insmed's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Insmed's significant trades, within a strike price range of $32.5 to $200.0, over the past month.</p>
<h3>Insmed Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766775710_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Options Call Chart" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766775710_0.png"/></p>

<h3>Noteworthy Options Activity:</h3>
<p></p><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$7.6</td>
<td>$7.0</td>
<td>$6.79</td>
<td>$200.00</td>
<td>$95.9K</td>
<td align="right">246</td>
<td align="right">137</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$146.0</td>
<td>$143.3</td>
<td>$146.0</td>
<td>$32.50</td>
<td>$73.0K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.06</td>
<td>$200.00</td>
<td>$58.1K</td>
<td align="right">246</td>
<td align="right">249</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$6.97</td>
<td>$200.00</td>
<td>$34.9K</td>
<td align="right">246</td>
<td align="right">364</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/20/26</td>
<td>$7.0</td>
<td>$6.5</td>
<td>$6.76</td>
<td>$200.00</td>
<td>$33.9K</td>
<td align="right">246</td>
<td align="right">471</td>
</tr>
</tbody>
</table><p></p>
<h3>About Insmed</h3>
<p>Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.</p>
<h3>Present Market Standing of Insmed</h3>
<ul>
<li>Currently trading with a volume of 476,194, the INSM's price is up by 1.45%, now at $180.0. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 55 days.</li>
</ul>
<h3>Professional Analyst Ratings for Insmed</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $220.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* An analyst from Goldman Sachs has decided to maintain their Buy rating on Insmed, which currently sits at a price target of $225. 
* An analyst from Cantor Fitzgerald persists with their Overweight rating on Insmed, maintaining a target price of $230. 
* An analyst from Guggenheim persists with their Buy rating on Insmed, maintaining a target price of $221. 
* Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Insmed, targeting a price of $195. 
* Maintaining their stance, an analyst from HC Wainwright &amp; Co. continues to hold a Buy rating for Insmed, targeting a price of $230. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Insmed, Benzinga Pro gives you real-time options trades alerts.</p>

INSM

<p>High-rolling investors show bearish sentiment on Insmed (NASDAQ:INSM), with 75% bearish and 12% bullish options trades. Benzinga's scanner identified 8 trades, focusing on a price range of $32.5 to $200.0. Insmed's stock is up 1.45% at $180.0, with analysts maintaining positive ratings and target prices between $195 and $230. Options trading is riskier but offers higher profit potential. Benzinga Pro provides real-time alerts for Insmed's options trades.</p>

A Closer Look at Insmed's Options Market Dynamics